Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Lipner (Warsaw, Poland), M. Lissy (Neu-Ulm, Germany), B. Dymek (Warsaw, Poland), K. Dzwonek (Warsaw, Poland), P. Dobrzanski (Warsaw, Poland), M. Kania (Warsaw, Poland), A. Golebiowski (Warsaw, Poland), S. Pikul (Warsaw, Poland). Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases. 5228

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial. Source: International Congress 2017 – Interstitial lung diseases (ILDs): novel pathogenetic pathways Year: 2017 Late Breaking Abstract - Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B). Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19 Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019